Propose a new Firefly-Fast Learning Network model based Intrusion-Detection System

Currently, effective Intrusion-detection systems (IDS) still represent one of the important security tools. However, hybrid models based on the IDS achieve better results compared with intrusion detection based on a single algorithm. But even so, the hybrid models based on traditional algorithms still face different limitations. This work is focused on providing two main goals; firstly, analysis based on the main methods and limitations of the most-recent hybrid model-based on intrusion detection, secondly, to propose a novel hybrid IDS model called FA-FLN based on the Firefly algorithm and Fast Learning Network

The Team Work Equipment Sdn.Bhd / Dzul Hizzam Zainal … [et al.]

The Team Work Equipment Sdn. Bhd will be establish on January 2004. The Team Work Equipment Sdn. Bhd are located at No.15, Jalan Togo 8, Taman Perindustrian Togo,Sri Damansara, 52200 Kuala Lumpur, Malaysia. Our main focus is serving, supply and rental of lighting, grip and camera for future film and commercial producer who are shooting especially in Klang Valley. In addition, today many new production houses don't have enough equipment for shooting and do their project performance. This location is chosen because it's strategic place nearby a production at Klang Valley. More over entertainment industry are developing in Malaysia. This business will be open on 1st January 2004 to production house, future film and commercial

An adaptive recovery method in compressed sensing of extracellular neural recording

ABSTRACT: A novel adaptive recovery method in the emerging compressed sensing theory is described and applied to extracellular neural recordings in order to reduce data rate in wireless neural recording systems. To strike a balance between high compression ratio and high spike reconstruction quality, a novel method that employs a group-sparsity recovery algorithm, prior information about the input neural signal, learning prior supports of spikes, and a matched wavelet technique is introduced. Our simulation results, using four different sets of real extracellular recordings from four distinct neural sources, show that our proposed method is effective, viable, and outperforms the state-of-the-art compressed sensing-based methods, in particular, when the number of the measurement is two times of the sparsity

Salvinia molesta dan Pistia stratiotes sebagai agen fitoremediasi dalam rawatan air sisa kumbahan

Akumulasi logam berat dan bahan pencemar ke dalam ekosistem akuatik memberi impak negatif kepada alam sekitar dan organisma akuatik. Salvinia molesta dan Pistia stratiotes merupakan spesies yang mempunyai kadar pertumbuhan yang cepat dan berkemampuan dalam mengakumulasi logam berat dan menyerap nutrien menjadikan ia sesuai digunakan untuk merawat air sisa melalui kaedah bioteknologi iaitu fitoremediasi. Kajian ini dijalankan untuk menentukan kualiti air sisa kumbahan sebelum dan selepas rawatan menggunakan kaedah fitoremediasi. Selain itu, objektif kajian ini juga adalah untuk menilai keberkesanan Salvinia molesta dan Pistia stratiotes sebagai agen fitoremediasi bagi rawatan air sisa. Sampel tumbuhan akuatik berbeza berat iaitu 10, 20 dan 30 g diuji untuk rawatan tersebut. Ujian ANOVA satu hala menunjukkan perbezaan kadar pengurangan jumlah pepejal terampai dan ammoniakal nitrogen yang bererti (p<0.05) bagi 10, 20 dan 30 g Pistia stratiotes dan Salvinia molesta sepanjang kajian dijalankan iaitu daripada hari 0 sehingga hari ke-7. Keputusan kajian juga menunjukkan 30 dan 20 g Pistia stratiotes dan Salvinia molesta dapat menyingkirkan jumlah pepejal terampai dan ammoniakal nitrogen dengan lebih cepat berbanding berat tumbuhan 10 g. Ujian ANOVA satu hala juga tidak menunjukkan perbezaan yang bererti bagi kadar pengurangan jumlah pepejal terampai dan ammoniakal nitrogen antara Pistia stratiotes dan Salvinia molesta

The Team Work Equipment Sdn. Bhd. / Dzul Hizzam Zainal ... [et al.]

The Team Work Equipment Sdn. Bhd will be establish on January 2004. The Team Work Equipment Sdn. Bhd are located at No. 15, Jalan Togo 8, Taman Perindustrian Togo,Sri Damansara, 52200 Kuala Lumpur, Malaysia

Numerical and experimental studies of a capillary-tube embedded PCM component for improving indoor thermal environment

This paper aims to analyse the thermal characteristics of a novel system of Capillary Tubes embedded in a Phase Change Material (CT-PCM) as part of active building environmental design for energy conservation and the improvement of indoor thermal environment. The CT-PCM system is proposed based on the concept that low-grade energy utilisation potential could be harnessed and maximised by buildings’ radiant heating/cooling systems and phase change material. The CT-PCM component is first built in the laboratory, and the thermal characteristics of the CT-PCM are investigated through a set of thermal response experiments. In addition, a simplified model is developed to assess the long-term thermal performance of the CT-PCM system for its application during a strategical system design stage. To ensure the robustness of the numerical model in the assessment of the thermal performance of the system, the developed model is evaluated against the experiments under a set of dynamic thermal boundary conditions. The evaluation process revealed that when the flow rate of thermal fluids in the CT-PCM system is more than 800 ml/min, the simulation results of the proposed simplified model is in a good agreement with the experiment. When the flow rate in the capillary tube is smaller than 800 ml/min, the correction factors are derived to address the non-uniformity of temperature distribution

Safety Outcomes During Pediatric GH Therapy : Final Results From the Prospective GeNeSIS Observational Program

Altres ajuts: Financial Support: GeNeSIS was sponsored by Eli Lilly and Company (Indianapolis, IN). In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. Disclosure Summary: C.J.C. and N.J. are employees and stockholders ofEliLilly and Company (Indianapolis, IN).W.F.B. and A.G.Z. are former employees and are stockholders of Lilly. C.L.D., T.H., M.M., and R.G.R. are former members of the GeNeSIS International Advisory Board; S.L., J.P.S., A.R.-U., and M.P. have served as regional advisors. B.P. has consulted for Eli Lilly Italia SpA, and E.C. has received grant support from Lilly. W.F.B. also reports heis aconsultant forAmmonett Pharma,Lilly Germany, and Merck KGaA Darmstadt. C.L.D. also reports receipt of grants, consultancy honoraria, and speaker fees from Lilly,EMD Serono, and Sandoz; grants fromOpko Prolor, Pfizer, and Versatis; honoraria and speaker fees from Roche; honoraria from Pfizer; and speaker fees from Novo Nordisk. The remaining authors have nothing to disclose.Safety concerns have been raised regarding premature mortality, diabetes, neoplasia, and cerebrovascular disease in association with GH therapy. To assess incidence of key safety outcomes. Prospective, multinational, observational study (1999 to 2015). A total of 22,311 GH-treated children from 827 investigative sites in 30 countries. Children with growth disorders. GH treatment. Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) with 95% CIs for mortality, diabetes, and primary cancer using general population registries. Predominant short stature diagnoses were GH deficiency (63%), idiopathic short stature (13%), and Turner syndrome (8%), with mean ± SD follow-up of 4.2 ± 3.2 years (∼92,000 person-years [PY]). Forty-two deaths occurred in patients with follow-up, with an SMR (95% CI) of 0.61 (0.44, 0.82); the SMR was elevated for patients with cancer-related organic GH deficiency [5.87 (3.21, 9.85)]. Based on 18 cases, type 2 diabetes mellitus (T2DM) risk was elevated [SIR: 3.77 (2.24, 5.96)], but 72% had risk factors. In patients without cancer history, 14 primary cancers were observed [SIR: 0.71 (0.39, 1.20)]. Second neoplasms occurred in 31 of 622 cancer survivors [5.0%; 10.7 (7.5, 15.2) cases/1000 PY] and intracranial tumor recurrences in 67 of 823 tumor survivors [8.1%; 16.9 (13.3, 21.5) cases/1000 PY]. All three hemorrhagic stroke cases had risk factors. GeNeSIS (Genetics and Neuroendocrinology of Short Stature International Study) data support the favorable safety profile of pediatric GH treatment. Overall risk of death or primary cancer was not elevated in GH-treated children, and no hemorrhagic strokes occurred in patients without risk factors. T2DM incidence was elevated compared with the general population, but most cases had diabetes risk factors. Safety of GH therapy was assessed in a pediatric observational study. Death and primary cancer rates were not higher than in the general population; T2DM rate was higher owing to risk factors

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Measurement of the top quark forward-backward production asymmetry and the anomalous chromoelectric and chromomagnetic moments in pp collisions at √s = 13 TeV

Abstract The parton-level top quark (t) forward-backward asymmetry and the anomalous chromoelectric (d̂ t) and chromomagnetic (μ̂ t) moments have been measured using LHC pp collisions at a center-of-mass energy of 13 TeV, collected in the CMS detector in a data sample corresponding to an integrated luminosity of 35.9 fb−1. The linearized variable AFB(1) is used to approximate the asymmetry. Candidate t t ¯ events decaying to a muon or electron and jets in final states with low and high Lorentz boosts are selected and reconstructed using a fit of the kinematic distributions of the decay products to those expected for t t ¯ final states. The values found for the parameters are AFB(1)=0.048−0.087+0.095(stat)−0.029+0.020(syst),μ̂t=−0.024−0.009+0.013(stat)−0.011+0.016(syst), and a limit is placed on the magnitude of | d̂ t| &lt; 0.03 at 95% confidence level. [Figure not available: see fulltext.